Key clinical point: A once-daily oral melanocortin-1 receptor agonist holds the promise of markedly improved quality of life in patients with erythropoietic protoporphyria.

Major finding: Dersimelagon significantly increased pain-free sunlight exposure time in patients with erythropoietic protoporphyria.

Study details: This phase 2, double-blind, placebo-controlled, 16-week, multicenter clinical trial included 102 adults with erythropoietic protoporphyria.

Disclosures: The presenter is employed by Mitsubishi Tanabe Pharma Development America, the study sponsor.